Agenus (NASDAQ:AGEN – Get Rating) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.11, MarketWatch Earnings reports. During the same period in the previous year, the company posted ($0.27) earnings per share.
Shares of AGEN stock opened at $1.51 on Thursday. The stock’s 50-day moving average price is $2.41 and its 200 day moving average price is $2.91. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $408.11 million, a PE ratio of -8.39 and a beta of 1.26. Agenus has a 52-week low of $1.50 and a 52-week high of $6.79.
AGEN has been the topic of several research reports. B. Riley dropped their price objective on Agenus from $11.00 to $8.00 in a report on Thursday, March 3rd. Zacks Investment Research lowered Agenus from a “hold” rating to a “sell” rating in a research report on Friday, March 4th. HC Wainwright boosted their price objective on Agenus from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 2nd. Finally, StockNews.com initiated coverage on shares of Agenus in a research report on Thursday, March 31st. They set a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Agenus currently has a consensus rating of “Hold” and a consensus price target of $8.75.
About Agenus (Get Rating)
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.